Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cryptorchidism (author's transl)].

P Stubbe

    Monatsschrift Fur Kinderheilkunde
    |June 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    The optimal age for cryptorchidism treatment is two years. Medical options like human chorionic gonadotropin (HCG) or luteotropic hormone-releasing hormone (LH-RH) offer alternatives to surgery, with LH-RH potentially providing a painless treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Autoimmune thyreoiditis in childhood--epidemiology, clinical and laboratory findings in 61 patients.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·1997
    Same author

    Growth response to recombinant human growth hormone of mammalian cell origin in prepubertal growth hormone-deficient children during the first two years of treatment.

    Hormone research·1992
    Same author

    Recombinant human growth hormone and oxandrolone in treatment of short stature in girls with Turner syndrome.

    Hormone research·1992
    Same author

    [Hypophyseal microprolactinoma as a cause of delayed puberty].

    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde·1989
    Same author

    Effect of different oestrogen doses on final height reduction in girls with constitutional tall stature.

    European journal of pediatrics·1989
    Same author

    Spontaneous growth in Turner's syndrome.

    Acta paediatrica Scandinavica. Supplement·1988
    Same journal

    [Diagnosis of retinal vascular changes in diabetic children by means of fluorescein-angiography (author's transl)].

    Monatsschrift fur Kinderheilkunde·1980
    Same journal

    [Epidemiological and socio-psychological aspects of accidents in childhood (author's transl)].

    Monatsschrift fur Kinderheilkunde·1980
    Same journal

    [Biochemical changes after endurance exercise in children and juveniles (author's transl)].

    Monatsschrift fur Kinderheilkunde·1980
    Same journal

    [Bronchial asthma in a female child of 3 1/2: the role of family dynamics (author's transl)].

    Monatsschrift fur Kinderheilkunde·1980
    Same journal

    [Diagnostic significance of lactate and lysozyme concentrations in cerebrospinal fluids inchildren with meningitis (author's transl)].

    Monatsschrift fur Kinderheilkunde·1980
    Same journal

    [Clinico-pathological data in infants with different types of nephrotic syndrome (author's transl)].

    Monatsschrift fur Kinderheilkunde·1980
    See all related articles

    Area of Science:

    • Pediatric Endocrinology
    • Urology
    • Reproductive Medicine

    Context:

    • Cryptorchidism, or undescended testes, requires timely intervention.
    • Surgical correction is indicated for ectopic testes, inguinal hernias, and post-operative testicular malposition.
    • Medical management is an alternative for fixed inguinal, retractile, or abdominal testes.

    Purpose:

    • To review the optimal timing and treatment modalities for cryptorchidism.
    • To evaluate the efficacy of medical treatments, including human chorionic gonadotropin (HCG) and luteotropic hormone-releasing hormone (LH-RH).
    • To explore LH-RH as a potentially advantageous alternative to HCG.

    Summary:

    • Treatment for cryptorchidism should commence at two years of age, supported by pathological and anatomical evidence.

    Related Experiment Videos

  • Human chorionic gonadotropin (HCG) achieves an average 50% success rate in medical treatment.
  • Intranasal luteotropic hormone-releasing hormone (LH-RH) presents a promising alternative, potentially offering painlessness and avoiding androgenic side effects while matching HCG's success rates.

    • Impact:

    • Establishes a recommended treatment age for cryptorchidism.
    • Provides evidence-based insights into the comparative efficacy of HCG and LH-RH therapies.
    • Highlights LH-RH as a potentially superior medical treatment option for cryptorchidism.